cvs novo nordisk - Search News

News

Novo missed its sales estimates on weight-loss drug Wegovy

Why Novo missed its sales estimates on weight-loss drug Wegovy: CEO

Investors are worried Novo Nordisk's competition with Eli Lilly is heating up and that the first-to-market GLP-1 leader is losing ground.

Reuters on MSN · 9h

Novo Nordisk hopes to see US Wegovy sales recover soon

Drugmaker Novo Nordisk expects Wegovy weight-loss drug sales in the United States to start to recover once a ban on compound copycats is enforced this month, its CEO said on Wednesday after the company cut its 2025 forecasts.

Bloomberg on MSN · 13h

Novo Nordisk Gains as CFO Touts Wegovy’s Rebound Potential

Novo Nordisk A/S surged on expectations that some competition for its blockbuster obesity shot Wegovy will subside, paving the way for a sales rebound later this year.

Novo Nordisk Cuts Guidance

Financial Times · 10h

Novo Nordisk cuts forecasts after replica obesity drugs hit US take-up

Wegovy maker expects second-half rise in business that used to go to pharmacies’ custom-made ‘compounded’ versions

AOL · 12h

Novo Nordisk beats on Q1 earnings, cuts 2025 outlook

Novo reported $11.9 billion in revenues, in line with Wall Street's estimates, and beat on adjusted earnings per share (EPS) with 99 cents per share compared to estimates of 94 cents per share. Sales of the company's blockbuster GLP-1 drugs, up 13% year-over-year, drove the quarter's results, despite a slight slowdown in weight loss sales.

The Wall Street Journal on MSN · 11h

Novo Nordisk Investors Breathe Sigh of Relief Despite Guidance Hit From Copycat Drugs

Shares rallied Wednesday even after the drugmaker lowered its full-year guidance as alternative versions of its blockbuster weight-loss and diabetes drugs in the U.S. hold back its sales.

6don MSN

CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans

CVS Health said it will significantly expand access to Novo Nordisk's blockbuster weight loss drug Wegovy for patients ...

3 major takeaways from Novo Nordisk's Q1 earnings

Novo Nordisk (NVO) topped first quarter earnings estimates while its revenue figures came in line with analyst expectations ...

BioPharma Dive6d

CVS strikes Wegovy deal with Novo Nordisk

The deal could expand access to its in-demand obesity drug at the expense of Eli Lilly, whose shares fell by double digits on ...

Fierce Pharma9h

Novo's Wegovy takes a hit from compounders, but company expects faster second-half growth

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity ...

Novo Nordisk Q1 Earnings Review: Forget Revenue Miss, Buy Semaglutide Hype

Novo Nordisk A/S' Q1 earnings reveal strong growth in semaglutide-driven sales despite a slight revenue miss. Learn more ...

6don MSN

CVS Drops Lilly’s Zepbound as Preferred Drug in Win for Novo

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Novo Nordisk's Wegovy Sales Surge 85% But Compounded Weight Loss Drugs In US Impacts Annual Outlook

Novo Nordisk Q1 sales missed estimates despite strong growth in Wegovy and Ozempic, prompting a cut to its 2025 guidance amid ...

5don MSN

Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday

GLP-1 drug prices are falling. That's good news for patients, but perhaps not such good news for pharmaceutical stock ...

8hon MSN

Healthy Returns: Novo Nordisk’s Wegovy deal with CVS won't derail Eli Lilly's obesity market dominance

Eli Lilly won't lose its grip on the weight loss market despite recent investor concerns. Meanwhile, Zocdoc releases an AI-powered scheduling assistant.

Results that may be inaccessible to you are currently showing.

Hide inaccessible results